Senior Technical Manager
India
Job Description
Senior Technical Manager
Sholinganallur, Tamil Nadu

Job Summary

The Project Manager will coordinate the initial cross-functional assessment of nitrosamine 
risk for biotherapeutic products, including proteins and cell and gene therapies. The 
immediate objective is to determine whether existing paper-based risk assessments and 
supporting documentation remain adequate against current regulatory expectations, and 
to define any evidence gaps, potential follow-up work, and an indicative scope and 
resource estimate. This is an assessment-first role; confirmatory testing or remediation 
should not be assumed.

Key Responsibilities

Stakeholder coordination: Partner with the designated Biotherapeutics leads to 
identify and engage the relevant drug substance, drug product, MSAT Material 
Sciences, and R&D Material Sciences SMEs, keeping outreach focused on the 
assessment.
• Assessment workplan: Establish a focused workplan with clear owners, 
milestones, decisions, and dependencies that leads to an initial scope and 
resource estimate, aligned with the existing Synthetics nitrosamine program.
• Evidence review: Under SME direction, coordinate the review of existing 
biotherapeutics nitrosamine risk evaluations, underlying assumptions, and 
supporting evidence, including material, process, water, packaging, and storage 
inputs.
• Technical discussions: Arrange targeted technical discussions and document 
decisions, open questions, evidence requests, and follow-up actions. Facilitate 
comparison of assumed biotherapeutics nitrosamine levels against Synthetics 
assumptions, and of assumed versus measured Synthetics levels.
• Gap assessment: Track SME conclusions on whether existing paper-based 
evaluations are sufficient. Where gaps are identified, coordinate definition of any 
further assessment, testing, or remediation needs, distinguishing between lifecycle 
management products and products in development.
• Decision-ready reporting: Consolidate agreed findings, open questions, options, 
indicative scope, timing, and resource needs into a concise, decision-ready update 
with clear ownership of next steps. Technical conclusions and testing decisions 
remain with the accountable SMEs.

Skill Requirements

Mandatory: Direct, hands-on experience with nitrosamine risk assessment or 
related investigations for biotherapeutic products (e.g., proteins, monoclonal 
antibodies, cell and gene therapies, or antibody–drug conjugates). General biologics 
experience, or nitrosamine experience limited to Synthetics, does not meet this 
requirement.
• Project management or coordination experience in a GMP biopharmaceutical 
environment, including cross-functional document review, action tracking, and 
evidence-based scope planning.
• Working knowledge of biotherapeutic drug substance and drug product risk factors, 
nitrosamine assessment documentation, and the distinction between risk 
evaluation, confirmatory testing, and remediation.
• Demonstrated ability to work effectively with scientific, quality, and regulatory 
SMEs; translate technical discussions into a clear plan and resource estimate; and 
manage sensitive scope questions without making scientific or regulatory decisions 
on their behalf

Other Requirements

Information at a Glance

Why HCLTech?

At HCLTech, you'll supercharge your potential. You'll find your career. And you'll find your spark. All at a place that knows that helping its customers stay on top starts by putting its people first.

HCLTech is a global technology company, home to more than 230,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG, and Public Services. Consolidated revenues as of 12 months ending September 2026 totaled $14.8 billion.